Q-omics provides the consensus-scored MAP3K4 profile across patient tissues and cancer cell-line models. MAP3K4 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, MAP3K4 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, MAP3K4 RNA expression shows 21,509 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight MESO, THCA, and KIRP as cancer lineages where MAP3K4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAP3K4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAP3K4 survival associations across molecular data types. MAP3K4 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (9) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAP3K4 RNA expression–survival associations across cancer types. High MAP3K4 expression shows unfavorable associations in MESO, LIHC, STAD, OV, KICH and ACC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for MAP3K4 RNA expression.
This table summarizes MAP3K4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for MAP3K4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAP3K4 shows lower tumor expression in THCA, LUAD, KICH and BRCA and higher tumor expression in COAD and LIHC. The THCA box plot shows higher MAP3K4 RNA expression in normal versus tumor tissue (log2 FC = −0.887, t-test p < 0.001).
This table shows molecular features associated with MAP3K4 in patient tissues and cancer cell lines. In patient samples, MAP3K4 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, MAP3K4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
